Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Huntingtin (Huntington Disease Protein or HTT) – Overview
Huntingtin (Huntington Disease Protein or HTT) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Huntingtin (Huntington Disease Protein or HTT) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Huntingtin (Huntington Disease Protein or HTT) – Companies Involved in Therapeutics Development
AFFiRiS AG
Alnylam Pharmaceuticals Inc
Anima Biotech Inc
Arvis Inc
Atalanta Therapeutics Inc
Ceptur Therapeutics Inc
Dystrogen Therapeutics SA
Enzer Biosciences LLC
F. Hoffmann-La Roche Ltd
Locabio Inc
Neurimmune Holding AG
Novartis AG
Ophidion Inc
Origami Therapeutics Inc
Passage Bio Inc
Primary Peptides Inc
PTC Therapeutics Inc
reMYND NV
ResQ Biotech
Takeda Pharmaceutical Co Ltd
UniQure NV
Voyager Therapeutics Inc
Vybion Inc
Wave Life Sciences Ltd
Huntingtin (Huntington Disease Protein or HTT) – Drug Profiles
ALN-HTT – Drug Profile
Product Description
Mechanism Of Action
History of Events
AMT-130 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Antisense Oligonucleotides to Inhibit HTT for Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
Antisense Ri Oligonucleotide to Inhibit HTT for for Huntington Disease – Drug Profile
Product Description
Mechanism Of Action
History of Events
braplam hydrochloride – Drug Profile
Product Description
Mechanism Of Action
History of Events
C-617 – Drug Profile
Product Description
Mechanism Of Action
History of Events
DYST-201 – Drug Profile
Product Description
Mechanism Of Action
History of Events
ENZ-001 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Inhibit HTT for Huntington Disease – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Inhibit HTT for Huntington’s disease – Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Inhibit Huntingtin for Huntington Disease – Drug Profile
Product Description
Mechanism Of Action
History of Events
HTT – Drug Profile
Product Description
Mechanism Of Action
Huntington Disease – Drug Profile
Product Description
Mechanism Of Action
Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
History of Events
INT-41 – Drug Profile
Product Description
Mechanism Of Action
History of Events
mHTT – Drug Profile
Product Description
Mechanism Of Action
History of Events
NI-302 – Drug Profile
Product Description
Mechanism Of Action
History of Events
PP-005 – Drug Profile
Product Description
Mechanism Of Action
PTC-518 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombint Peptides to Inhibit Huntingtin for Huntington Disease – Drug Profile
Product Description
Mechanism Of Action
ReS-18H – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit HTT for Huntington Disease – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Inhibit HTT for Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit Huntingtin Protein for Huntington Disease – Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecules to Target HTT for Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
Synthetic Peptide to Inhibit Huntingtin Protein for Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
TAK-686 – Drug Profile
Product Description
Mechanism Of Action
History of Events
tominersen – Drug Profile
Product Description
Mechanism Of Action
History of Events
Vaccine to Target Huntingtin for Huntington’s Disease – Drug Profile
Product Description
Mechanism Of Action
WVE-003 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Huntingtin (Huntington Disease Protein or HTT) – Dormant Products
Huntingtin (Huntington Disease Protein or HTT) – Discontinued Products
Huntingtin (Huntington Disease Protein or HTT) – Product Development Milestones
Featured News & Press Releases
Jun 23, 2022: uniQure announces update on low-dose cohort in phase I/II clinical trial of AMT-130 gene therapy for the treatment of Huntington’s disease
Mar 30, 2022: PTC Therapeutics announces initiation of PIVOT-HD phase 2 clinical trial to evaluate PTC518 in patients with Huntington’s Disease
Mar 21, 2022: uniQure announces completion of patient enrollment in the first two cohorts of its phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease
Feb 07, 2022: uniQure announces dosing of first patients in European open-label clinical trial of AMT-130 gene therapy in Huntington’s disease
Jan 18, 2022: Ionis’ partner to evaluate tominersen for Huntington’s disease in new Phase 2 trial
Dec 16, 2021: uniQure announces clinical update on first patients in phase I/II clinical trial of AMT-130 gene therapy for the treatment of Huntington’s Disease
Dec 16, 2021: Novartis receives FDA Fast Track desigtion for braplam (LMI070) for the treatment of Huntington’s Disease
Nov 02, 2021: uniQure announces latest positive recommendation from data safety monitoring board in phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease
Sep 20, 2021: PTC Therapeutics to host conference call to discuss results of PTC518 phase 1 study for Huntington’s disease program
Sep 09, 2021: Wave Life Sciences announces initiation of dosing in phase 1b/2a SELECT-HD clinical trial of WVE-003 in Huntington’s disease
Aug 30, 2021: uniQure announces completion of additiol patient procedures following positive recommendation from data safety monitoring board in phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease
Jul 23, 2021: Novartis stops development of braplam for SMA
Jun 16, 2021: uniQure announces enrollment of first two patients in second cohort of phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease
May 27, 2021: uniQure announces positive recommendation to advance phase I/II Clinical Trial of AMT-130 for the treatment of Huntington’s Disease
Apr 27, 2021: Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington’s Disease Therapeutics Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by AFFiRiS AG, 2022
Pipeline by Alnylam Pharmaceuticals Inc, 2022
Pipeline by Anima Biotech Inc, 2022
Pipeline by Arvinas Inc, 2022
Pipeline by Atalanta Therapeutics Inc, 2022
Pipeline by Ceptur Therapeutics Inc, 2022
Pipeline by Dystrogen Therapeutics SA, 2022
Pipeline by Enzerna Biosciences LLC, 2022
Pipeline by F. Hoffmann-La Roche Ltd, 2022
Pipeline by Locanabio Inc, 2022
Pipeline by Neurimmune Holding AG, 2022
Pipeline by Novartis AG, 2022
Pipeline by Ophidion Inc, 2022
Pipeline by Origami Therapeutics Inc, 2022
Pipeline by Passage Bio Inc, 2022
Pipeline by Primary Peptides Inc, 2022
Pipeline by PTC Therapeutics Inc, 2022
Pipeline by reMYND NV, 2022
Pipeline by ResQ Biotech, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Pipeline by UniQure NV, 2022
Pipeline by Voyager Therapeutics Inc, 2022
Pipeline by Vybion Inc, 2022
Pipeline by Wave Life Sciences Ltd, 2022
Dormant Projects, 2022
Discontinued Products, 2022